Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery
Open Access
- 23 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (3) , 382-389
Abstract
Prothrombin complex concentrates (PCCs) are sometimes used as ‘off label’ for excessive bleeding after cardiopulmonary bypass (CPB). The main objective of this study was to retrospectively evaluate the clinical and biological efficacy of PCC in this setting. We reviewed the charts of all patients who had undergone cardiac surgery under CPB in our institution for 2 years. Patients treated for active bleeding with haemostatic therapy were identified. Chest tube blood loss was quantified postoperatively in the first 24 h. Coagulation parameters were recorded at intensive care unit admission and in the patient's first 24 h. Thromboembolic complications were also ascertained. Seventy-seven patients out of the 677 studied (11.4%) were included: PCC was solely administered in 24 patients (group I), fresh frozen plasma in 26 (group II) and both in 27 (group III). The mean dose of PCC was 10.0 UI/kg ± 3.5 for group I vs 14.1 UI/kg ± 11.2 for group III (P = 0.09). Initial blood loss in the first hour was different between the three groups (P = 0.05): 224 ± 131 ml for group I, 369 ± 296 ml for group II and 434 ± 398 ml for group III. Only group I vs group III presented a significant difference (P = 0.02). Variations of blood loss over time were no different according to the treatment groups (P = 0.12). Reductions in blood loss expressed in percentage showed no difference between the three groups after 2 h: 54.5% (68.6–30.8) for group I; 45.0% (81.6–22.2) for group II; 57.6 (76.0–2.1) for group III; (P = 0.89). Re-exploration for bleeding involved 1 patient in group I (4%), 2 in group II (8%) and 10 in group III (37%) (P = 0.002). Except for fibrinogen, variations of prothrombin time, activated partial thromboplastin time and platelets with time were not different according to the treatment groups. Cerebral infarction occurred in one patient in group II. Administration of low-dose of PCC significantly decreased postoperative bleeding after CPB.Keywords
This publication has 24 references indexed in Scilit:
- First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood Transfusion in Cardiovascular SurgeryAnesthesiology, 2011
- Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic reviewCritical Care, 2011
- Prevention and treatment of coagulopathy in patients receiving massive transfusionsVox Sanguinis, 2011
- The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleedingEuropean Journal of Cardio-Thoracic Surgery, 2011
- Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicityCritical Care, 2011
- Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine modelBritish Journal of Anaesthesia, 2010
- Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: A prospective observational studyThrombosis Research, 2010
- Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized studyVox Sanguinis, 2010
- Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleedingCritical Care, 2009
- Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgeryThrombosis and Haemostasis, 2009